Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Oct;29(10):4233-8.

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

Martin Kropff  1 , Joachim Kienast, Guido Bisping, Wolfgang E Berdel, Birgit Gaschler-Markefski, Peter Stopfer, Martin Stefanic, Gerd Munzert
Affiliations
  • PMID: 19846979
Free article
Clinical Trial

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

Martin Kropff et al. Anticancer Res. 2009 Oct.
Free article

Abstract

Background: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of BIBF 1120, a triple angiokinase inhibitor administered once-daily in patients with advanced multiple myeloma.

Patients and methods: This Phase I study included 17 patients. Planned dose escalations of BIBF 1120 were 100, 200, 250 and 300 mg. Safety and pharmacokinetic (PK) assessments were performed.

Results: Two DLTs (200 and 250 mg) occurred due to increased gamma-glutamyltransferase levels (CTC grade 3). The 250 mg dose was well tolerated; no dose escalation beyond 250 mg was made. The most common adverse events included diarrhoea, nausea and vomiting. No detectable deviation from dose linear PKs was observed. Regarding tumour control, two patients had stable disease for > or = 4 months.

Conclusion: BIBF 1120 was safe and well tolerated up to 250 mg/day. The MTD was not reached.

PubMed Disclaimer

Publication types

LinkOut - more resources